InAADR

Protein Information

Protein Name: Parathyroid hormone (P01270)
Gene Name: PTH
Description: Parathyroid hormone precursor (Parathyrin) (PTH) (Parathormone)
PDB ID: 1BWX
Protein Family:
Protein Category:
Protein Name: Parathyroid hormone (Q03431)
Gene Name: PTHR1
Description: Parathyroid hormone/parathyroid hormone-related peptide receptor precursor (PTH/PTHr receptor) (PTH/PTHrP type I receptor)
PDB ID: 1BL1
Protein Family:
Protein Category: Membrane Receptors

This panel provides drug-protein interaction and their ADRs along with references

Interacting Drugs Toxicity Mechanism Reference
Acetazolamide Acidosis Because parathyroid hormone@ 1@25-dihydroxyvitamin D and carbonic anhydrase are thought to be involved in bone buffering@the marked acidosis seen in haemodialysis patients treated with acetazolamide may be due to impaired parathyroid hormone-mediated bone buffering [ ADR Type 2 ] Severe metabolic acidosis and disturbances of calcium metabolism induced by acetazolamide in patients on haemodialysis
Calcitriol Acute Effects Acute effects of intravenous 1 alpha-hydroxycholecalciferol on parathyroid hormone@ osteocalcin and calcitriol in man [ ADR Type 1 ] Acute effects of intravenous 1 alpha-hydroxycholecalciferol on parathyroid hormone, osteocalcin and calcitriol in man
Dehydrated Alcohol Hyperparathyroidism The changes in parathyroid hormone are not consistent and since there is no greater incidence of hyperparathyroidism in alcoholic patients@ it SUGGESTS that alcohol does not have a long-term effect on the parathyroid glands. [ ADR Type 1 ] Alcohol and bone disease Alcohol
Furosemide Bone Demineralization Four preterm infants receiving long-term furosemide therapy were examined for hypercalciuria@ hyperparathyroidism@ renal calcification@ and bone demineralization Three of them had high serum concentrations of parathyroid hormone [ ADR Type 2 ] Secondary hyperparathyroidism and bone disease in infants receiving long-term furosemide therapy
Furosemide Hypercalciuria Four preterm infants receiving long-term furosemide therapy were examined for hypercalciuria@ hyperparathyroidism@ renal calcification@ and bone demineralization Three of them had high serum concentrations of parathyroid hormone [ ADR Type 2 ] Secondary hyperparathyroidism and bone disease in infants receiving long-term furosemide therapy
Furosemide Hyperparathyroidism Four preterm infants receiving long-term furosemide therapy were examined for hypercalciuria@ hyperparathyroidism@ renal calcification@ and bone demineralization Three of them had high serum concentrations of parathyroid hormone [ ADR Type 2 ] Secondary hyperparathyroidism and bone disease in infants receiving long-term furosemide therapy
Furosemide Renal Calcification Four preterm infants receiving long-term furosemide therapy were examined for hypercalciuria@ hyperparathyroidism@ renal calcification@ and bone demineralization Three of them had high serum concentrations of parathyroid hormone [ ADR Type 2 ] Secondary hyperparathyroidism and bone disease in infants receiving long-term furosemide therapy
glucocorticoid Osteoporosis People also develop osteoporosis during glucocorticoid therapy and respond to dietary salt supplements by increasing urinary calcium excretion and parathyroid hormone [ ADR Type 1 ] Effects of NaCl on calcium balance, parathyroid function and hydroxyproline excretion in prednisolone-treated rats consuming low calciumdiet
Paricalcitol Adverse Oversuppression Of Pth Paricalcitol increased serum calcium levels and decreased PTH and bone alkaline phosphatase levels (all P [ ADR Type 1 ] A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol
Urea Renal Failure Patients with the highest urea percentiles showed significantly higher plasma levels of phosphorus and parathyroid hormone and significantly lower hemoglobin concentrations and bicarbonate levels@which lead to chronic renal failure [ ADR Type 2 ] Urea percentiles in children with chronic renal failure Data from the ItalKid

This panel provides information on drug category

Toxicity Source

InAADR: Drug-Protein-ADRs database